Genomic determinants of PI3K pathway inhibitor response in cancer
The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in cancer as a result of genetic (e.g. amplifications, mutations, deletions) and epigenetic (e.g. methylation, non-coding RNA overexpression/downregulation) aberrations targeting its key components. Several lines of evidence demons...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00109/full |